

GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit

FDA EUA approved

- Continued of the second of the
- Currently Available Antibody Tests

 HRP

 RBD domain

 Neutralizing antibody

 Neutralizing antibody

 Neutralizing antibody

 Secondary antibody

 Non-Neutralizing antibody

 Non-Neutralizing antibody

 Secondary antibody

 Secon

 Detects antibodies in just 1 hour

- 96-well ELISA format
- Used with serum and plasma samples
- Comes with positive and negative controls
- Applications for both recovering and vaccinated patients

The cPass™ kit detects circulating neutralizing antibodies against SARS-CoV-2 that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein with the ACE2 cell surface receptor. This kit would be instrumental in vaccine and therapeutic development, and will also help in current COVID-19 investigations of sero-prevalence, assessment of herd immunity, longevity of protective immunity, and tracking infection in animals.

Thomas No.	Mfr. No.	Positive % Agreement	Negative % Agreement
CHM00C922	L00847	100%	100%



